The document summarizes the evolution of the Indian pharmaceutical industry over several phases from 1970 to the present. It began with foreign company domination and a lack of organized Indian companies. From 1970-1980 the government instituted controls over drug prices and local companies began to grow. From 1980-1990 the industry expanded domestically and internationally. From 1990-2000 research became a greater focus. Currently India has over 3000 pharmaceutical companies and aims to be a global leader in drug manufacturing due to lower costs. The industry has seen steady growth between 13-14% in recent years.

1. Indian Pharma
Industry
By Balaji Roy
1

2. How?
2

3. How?
Footer Text 3

4. Generic drug
development
Footer Text 4

5. Pharma Value Chain
5

6. Indian Pharmaceutical
Evolution
6
Phase II
Government Control
•Indian Patent Act –
1970
•Drug prices
capped
•Local companies
begin to make an
impact
Phase III
Development
Phase
•Process
development
•Production
infrastructure
creation
•Export initiatives
Phase IV
Growth Phase
•Rapid expansion
of domestic market
•International
market
development
•Research
orientation
Phase V
Innovation and
Research
•New IP law
•Discovery Research
•Convergence
1970 1980 1990 2000 2010
Phase I
Early Years
•Market share
domination by
foreign
companies
•Relative
absence of
organized Indian
companies

7. India Market
• India saw its first pharmaceutical company in 1930,
Bengal Chemicals and Pharmaceuticals works
• Till 1970s Indian pharmaceutical market was non
existent
• Indian Pharmaceutical market currently stands at
approximately 23.6 bn USD**
• 10500 manufacturing units, 3000 pharma
companies*
7

8. Interesting Facts
• Branded generics dominate the retail market with
70-80% share
• Price levels and margins are low due to intense
competition
• India ranks 10th globally in terms if value, 3rd in terms
of volume
• Last 5 years the growth rate is ranging between 13-
14% as compared to 9% before that
8

9. Growth Drivers
5/8/2014Footer Text 9

10. Growth Predictions
5/8/2014Footer Text 10

11. Opportunities
• As per 'Pharma Vision 2020', the Government of India aims to
make India a global leader in end-to-end drug
manufacturing**
• Manufacturing costs in India are approximately 35-40 per cent
of those in the US due to low installation and manufacturing
costs**
• The biologics market will grow to 3 bn USD by 2020*
• The projected human resource requirement in the Indian
pharma sector is estimated to be about 21,50,000 by 2020**
• Industry Least affected by recession
11

12. Opportunities Contd.
• Due to increasing population and income levels,
demand for high-end drugs is expected to reach US$ 8
billion by 2015
• Expenditure on pharmaceuticals is likely to increase to
over 40 per cent of the total spending on healthcare by
households by 2015 from 28 per cent in 2007
• With 70 per cent of India's population residing in rural
markets, various pharma companies are investing in the
distribution network in rural areas
• Increased penetration of chemists, especially in the rural
parts of the country would make OTC drugs easily
available
12

13. Current Top Players -
India
13

14. US Contribution
14

15. US Generics Market share
15

16. Indian impact in US
16

17. Indian Pharma in
Speciality products
17

18. ANDA pipeline
18

19. US Acquisitions
5/8/2014Footer Text 19

20. USFDA Issues
20

21. Country wise Import
alerts
21

22. Factor wise comparison
22

23. Factor wise comparison
23

24. Factor wise comparison
24

25. Thank You!
25